Full text PDF (4.6MB) - Jurnalul de Chirurgie

Articole de sinteza Jurnalul de Chirurgie, Iasi, 2007, Vol. 3, Nr. 2 [ISSN 1584 – 9341]3. Boulton F. A hundred years of cascading - started by Paul Morawitz (1879-1936), a pioneer ofhaemostasis and transfusion. Transfus Med. 2006; 16(1): 1-10.4. Brinkhous KM. Plasma antihemophilic factor biological and clinical aspects. Sang. 1954; 25(7): 738-741.5. MacFarlane RG. An enzyme cascade in the blood clotting mechanism and its function as a biochemicalamplifier. Nature. 1964; 202: 498-499.6. Haulicǎ I. Hemostaza fiziologicǎ. Bucureşti: Editura Medicalǎ; 1989.7. Heemskerk JWH, Bevers EM, Lindhout T. Platelet activation and blood coagulation. Thromb Haemost.2002; 88: 186-194.8. Sune A, Bette-Bobillo P, Bienvenue A, Fellmann P, Devaux PF. Selective outside-inside translocationof aminophospholipids in human platelets. Biochemistry. 1987; 26(11): 2972-2978.9. Bevers EM, Tilly RH, Senden JM, Comfurius P, Zwaal RF. Exposure of endogenousphosphatidylserine at the outer surface of stimulated platelets is reversed by restoration ofaminophospholipid translocase activity. Biochemistry. 1989; 28(6): 2382-2387.10. Srivastava A, Wang J, Majumder R, Rezaie AR, Stenflo J, Esmon CT, Lentz BR. Localization ofphosphatidylserine binding sites to structural domains of factor Xa. J Biol Chem. 2002; 277(3):1855-1863.11. Banerjee M, Majumder R, Weinreb G, Wang J, Lentz BR. Role of procoagulant lipids in humanprothrombin activation, 2: soluble phosphatidylserine upregulates and directs factor X(a) to appropriatepeptide bonds in prothrombin. Biochemistry. 2002; 41(3): 950-957.12. Walsh PN, Lipscomb MS. Comparison of the coagulant activities of platelets and phospholipids. Br JHaematol. 1976; 33(1): 9-18.13. Miletich JP, Jackson CM, Majerus PW. Properties of the factor Xa binding site on human platelets. JBiol Chem. 1978; 253(19): 6908-6916.14. Nesheim ME, Furmaniak-Kazmierczak E, Henin C, Cote G. On the existence of platelet receptors forfactor V(a) and factor VIII(a). Thromb Haemost. 1993; 70(1): 80-86.15. Bolton-Maggs PH. The management of factor XI deficiency. Haemophilia. 1998; 4(4): 683-688.16. Sumner WT, Monroe DM, Hoffman M. Variability in platelet procoagulant activity in healthyvolunteers. Thromb Res. 1996; 81(5): 533-543.17. Bauchard BA, Catcher CS, Thrash BR, Adida C, Tracy PB. Effector cell protease receptor-1, a plateletactivation-dependent membrane protein, regulates prothrombinase-catalyzed thrombin generation. JBiol Chem. 1997; 272: 9244-9251.18. Kumar R, Beguin S, Hemker HC. The effect of fibrin clots and clot-bound thrombin on thedevelopment of platelet procoagulant activity. Thromb Haemost. 1995; 74(3): 962-968.19. Brummel KE, Paradis SG, Branda RF, Mann KG. Oral anticoagulation thresholds. Circulation. 2001;104(19): 2311-2317.20. Lasne D, Krenn M, Pingault V, Arnaud E, Fiessinger JN, Aiach M, Rendu F. Interdonor variability ofplatelet response to thrombin receptor activation: influence of PIA2 polymorphism. Br J Haematol.1997; 99(4): 819-823.21. Andrew M, Schmidt B, Mitchell L, Paes B, Ofosu F. Thrombin generation in newborn plasma iscritically dependent on the concentration of prothrombin. Thromb Haemost. 1990; 63(1): 27-30.22. Butenas S, van’t Veer C, Mann KG. “Normal” thrombin generation. Blood. 1999; 94(7): 2169-2178.23. Alberio L, Safa O, Clemetson KJ, Esmon CT, Dale GT. Surface expression and functionalcharacterization of alpha-granule factor V in human platelets: effects of ionophore A23187, thrombin,collagen, and convulxin. Blood. 2000; 95: 1694-1702.24. Bolton-Maggs PH. Factor XI deficiency and its management. Haemophilia. 2000; 6(suppl 1): 100-109.25. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb VascBiol. 2002; 22(9): 1381-1389.26. De Cristofaro R, De Candia E, Landolfi R, Rutella S, Hall SW. Structural and functional mappig of thethrombin domain involved in the binding to the platelet glycoprotein Ib. Biochemistry. 2001; 40(44):13268-13273.27. Andersen H, Greenberg DL, Fujikawa K, Xu W, Chung DW, Davie EW. Protease-activated receptor-1is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc Natl Acad Sci USA.1999; 96(20): 11189-11193.28. Suzuki H, Shima M, Kamisue S, Nakai H, Nogami K, Shibata M, Morichika S, Tonak I, Giddings JC,Yoshioka A. The role of platelet von Willebrand factor in the binding of factor VIII to activatedplatelets. Thromb Res. 1998; 90(5): 207-214.29. Beguin S, Kumar R, Keularts I, Seligsohn U, Coller BS, Hemker HC. Fibrin-dependent plateletprocoagulant activity requiremes GPIb receptors and son Willebrand factor. Blood. 1999; 93(2): 564-570.108